Stivarga

UK Pulls Stivarga From Cancer Drug Fund Endangering GIST Patients

The National Health Service (NHS) in the United Kingdom has announced plans to halt funding through the Cancer Drug Fund for regorafenib (Stivarga), thereby preventing GIST patients from having access to this life-saving medication.We at [...]

By |2018-09-10T09:36:55-04:00January 29th, 2015|Advocacy, News, Stivarga|

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By |2018-07-06T13:59:34-04:00January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|

Stivarga Approved for Canadian GIST Patients

Health Canada has expanded approval for the use of Stivarga to fight Gastrointestinal Stromal Tumours (GIST), according to an article from CNW. Bayer announced that Stivarga will now be available for treatment of adult patients with [...]

By |2014-04-17T13:24:36-04:00October 18th, 2013|Drug Treatment, News, Stivarga|

Stivarga approved to treat GIST patients in Japan

Stivarga has just been approved in Japan for the treatment of GIST. Keep reading for more information. Official Stivarga Press Release: [box style="quote"]Bayer HealthCare has received approval from the Japanese authorities (MHLW) for the marketing [...]

By |2013-09-04T11:09:26-04:00August 21st, 2013|Drug Treatment, News, Stivarga|

Stivarga becomes first FDA-approved third-line drug treatment for GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.

By |2014-09-14T11:30:49-04:00April 1st, 2013|Drug Treatment, News, Side Effects, Stivarga|

FDA approves Stivarga for advanced GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.

By |2014-09-14T11:31:07-04:00February 25th, 2013|Clinical Trials, Drug Treatment, News, Stivarga|

Clinical Trials update for February 2011

Bayer initiates a randomized Phase III trial of Regorafenib in GIST: On January 10, 2011 Bayer Healthcare in Berlin, Germany announced the initiation of a randomized phase III trial of Regorafenib (BAY 73-4506) for Gastrointestinal Stromal Tumor patients.

By |2014-09-17T10:15:34-04:00February 1st, 2011|Clinical Trials, News, Stivarga|

Recent Posts

Upcoming Events

  1. Symptom and Side Effect Management

    June 18 @ 12:00 PM - 1:00 PM
  2. GDOL Portland 2019

    GDOL Portland 2019

    June 22 @ 8:30 AM - 6:00 PM
  3. Life Fest 2020 New Orleans

    Life Fest New Orleans

    July 10, 2020 - July 12, 2020